ADHD
Neurology · 2005–2022
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| methylphenidate hydrochloride Treatment of attention deficit hyperactivity disorder (ADHD) in adults with a retrospective diagnosis of ADHD. | Mar 2022 | Recommended with restriction | 131 individuals ADHD Australia · ADHD Foundation |
| lisdexamfetamine Treatment of attention deficit hyperactivity disorder (ADHD) in patients diagnosed after the age of 18 years, with retrospective confirmation of symptoms… | Mar 2020 | Recommended with restriction | 194 individuals ADHD Australia |
| lisdexamfetamine Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–18 years who require continuous coverage over 12 hours. | Jul 2019 | Recommended with restriction | 116 individuals |
| guanfacine Treatment of attention deficit hyperactivity disorder (ADHD) as add-on therapy in patients aged 6-18 years who have failed to achieve an adequate response to… | Jul 2018 | Recommended with restriction | none received |
| lisdexamfetamine dimesilate Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6–18 years who have demonstrated a response to immediate-release dexamphetamine… | Jul 2014 | Recommended with restriction | 7 individuals |
| lisdexamfetamine Treatment of attention deficit hyperactivity disorder (ADHD) in patients diagnosed between the ages of 6 and 18 years who require continuous coverage over 13… | Jul 2013 | Not recommended | input received |
| methylphenidate hydrochloride Extension of PBS listing to include treatment of attention deficit hyperactivity disorder (ADHD) in patients diagnosed after the age of 18 years. | Jul 2012 | Recommended | unclear |
| atomoxetine hydrochloride Initial and continuing treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between the ages of 6 and 18 years inclusive, in patients where… | Jul 2008 | Recommended with restriction | no section in document |
| methylphenidate hydrochloride Attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–18 years who have demonstrated a response to immediate release… | Jul 2007 | Not recommended | no section in document |
| atomoxetine hydrochloride Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6–18 years where stimulant therapy (dexamphetamine or… | Jul 2006 | Not recommended | no section in document |
| atomoxetine hydrochloride Initial treatment of attention-deficit hyperactivity disorder (ADHD) in patients aged 6–18 years where treatment with dexamphetamine sulfate or methylphenidate… | Nov 2006 | Recommended with restriction | no section in document |
| methylphenidate hydrochloride Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6-18 years who have demonstrated a response to immediate release… | Nov 2006 | Recommended with restriction | no section in document |
| atomoxetine hydrochloride Initial treatment of attention-deficit hyperactivity disorder (ADHD) diagnosed between ages 6 and 18 years in patients unable to tolerate or contraindicated… | Nov 2005 | Not recommended | no section in document |
Who spoke
ADHD Australia · ADHD Foundation
What the PBS pays
$272M in government benefit over 2024–25, across 4,831,694 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| lisdexamfetamine | $170.1M |
| methylphenidate hydrochloride | $58.8M |
| guanfacine | $33.5M |
| Atomoxetine Hydrochloride | $4.9M |
| atomoxetine hydrochloride | $4.9M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| dexamfetamineAPO-DEXAMFETAMINE dexamfetamine sulfate 5 mg tablets blister packs | 1991 | 13 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.